These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10771421)

  • 21. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
    J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.
    Carbone V; Giglio M; Chung R; Huyton T; Adams J; Maccari R; Ottana R; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Mar; 45(3):1140-5. PubMed ID: 20036445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state.
    Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G
    J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
    El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
    J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural studies of aldo-keto reductase inhibition.
    Wilson DK; Nakano T; Petrash JM; Quiocho FA
    Adv Exp Med Biol; 1997; 414():435-42. PubMed ID: 9059648
    [No Abstract]   [Full Text] [Related]  

  • 26. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
    Mylari BL; Armento SJ; Beebe DA; Conn EL; Coutcher JB; Dina MS; O'Gorman MT; Linhares MC; Martin WH; Oates PJ; Tess DA; Withbroe GJ; Zembrowski WJ
    J Med Chem; 2003 Jun; 46(12):2283-6. PubMed ID: 12773033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
    Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
    Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
    Steuber H; Heine A; Podjarny A; Klebe G
    J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
    Wilson DK; Tarle I; Petrash JM; Quiocho FA
    Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9847-51. PubMed ID: 8234324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design synthesis and evaluation of novel aldose reductase inhibitors: The case of indolyl-sulfonyl-phenols.
    Koutsopoulos K; Lavrentaki V; Antoniou I; Kousaxidis A; Lefkopoulou M; Tsantili-Kakoulidou A; Kovacikova L; Stefek M; Nicolaou I
    Bioorg Med Chem; 2020 Aug; 28(15):115575. PubMed ID: 32631572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
    Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
    Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry.
    Potier N; Barth P; Tritsch D; Biellmann JF; Van Dorsselaer A
    Adv Exp Med Biol; 1997; 414():453-4. PubMed ID: 9059650
    [No Abstract]   [Full Text] [Related]  

  • 36. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Halogen-to-Hydrogen Bond Substitution on Human Aldose Reductase Inhibition.
    Fanfrlík J; Ruiz FX; Kadlčíková A; Řezáč J; Cousido-Siah A; Mitschler A; Haldar S; Lepšík M; Kolář MH; Majer P; Podjarny AD; Hobza P
    ACS Chem Biol; 2015 Jul; 10(7):1637-42. PubMed ID: 25919404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unusual binding mode of the 2S4R stereoisomer of the potent aldose reductase cyclic imide inhibitor fidarestat (2S4S) in the 15 K crystal structure of the ternary complex refined at 0.78 A resolution: implications for the inhibition mechanism.
    Zhao HT; Hazemann I; Mitschler A; Carbone V; Joachimiak A; Ginell S; Podjarny A; El-Kabbani O
    J Med Chem; 2008 Mar; 51(5):1478-81. PubMed ID: 18284183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
    Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
    J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
    Cousido-Siah A; Ruiz FX; Mitschler A; Porté S; de Lera ÁR; Martín MJ; Manzanaro S; de la Fuente JA; Terwesten F; Betz M; Klebe G; Farrés J; Parés X; Podjarny A
    Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):889-903. PubMed ID: 24598757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.